Evidence map›Paper›PMID 42259984›Full record

ArticleBiotechnology letters2026

Scaling up biomass production of Vishniacozyma victoriae and semi-commercial testing for post-harvest control of pome fruit disease.

M Florencia Gorordo, J Magdalena Fontanini, M Ester Lucca, M Paula Sangorrín

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M Florencia GorordoInstitute for Research and Development in Process Engineering, Biotechnology and Alternative Energies, (PROBIEN)-CONICET-UNCo, Buenos Aires 1400, 8300, Neuquén, Argentina.ORCID http://orcid.org/0000-0002-4333-978X
J Magdalena FontaniniInstitute for Research and Development in Process Engineering, Biotechnology and Alternative Energies, (PROBIEN)-CONICET-UNCo, Buenos Aires 1400, 8300, Neuquén, Argentina.ORCID http://orcid.org/0009-0006-5240-1756
M Ester LuccaPilot Plant for Industrial Microbiological Processes, (PROIMI)-CONICET, Avenida Belgrano y Pasaje Caseros, T4001MVB, San Miguel de TucumánTucumán, Argentina.ORCID http://orcid.org/0000-0002-3005-6000
M Paula SangorrínInstitute for Research and Development in Process Engineering, Biotechnology and Alternative Energies, (PROBIEN)-CONICET-UNCo, Buenos Aires 1400, 8300, Neuquén, Argentina. marcelasangorrin@conicet.gov.ar.ORCID http://orcid.org/0000-0001-7372-8359

Funding

Agencia Nacional de Promoción Científica y Tecnológica PICT 2019-1727Consejo Nacional de Investigaciones Científicas y Técnicas PUE0067
6 · The paper itself

Abstract

Postharvest losses of pome fruits such as apples and pears, primarily due to fungal pathogens, represent a significant challenge for global fruit production. Conventional chemical control strategies have raised concerns regarding food safety and environmental impact, highlighting the need for sustainable alternatives. This study aimed to scale up the biomass production of the epiphytic yeast Vishniacozyma victoriae NPCC 1263, a promising biological control agent (BCA) against postharvest diseases in pome fruits, and to evaluate its efficacy under semi-commercial conditions. BCA yeast biomass was produced using low-cost media based on cheese whey powder (CWP) and salts in laboratory (15 L) and pilot-scale (140 L) bioreactors, applying batch and semi-continuous cultivation modes. The volumetric oxygen transfer coefficient (k

Indexed as

FruitMalusPlant DiseasesBiomassBioreactorsPenicilliumPyrusBiocontrolBioreactor scale-upPome fruitsPostharvest diseasesYeast biomass production

Identifiers

PMID42259984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.